Targeting fibroblast activation protein inhibits tumor stromagenesis and growth in mice
Open accessThe DOI matches its Crossref record; 58 of the 58 references it cites were found in a registry or an index.
Abstract
Membrane-bound proteases have recently emerged as critical mediators of tumorigenesis, angiogenesis, and metastasis. However, the mechanisms by which they regulate these processes remain unknown. As the cell surface serine protease fibroblast activation protein (FAP) is selectively expressed on tumor-associated fibroblasts and pericytes in epithelial tumors, we set out to investigate the role of FAP in mouse models of epithelial-derived solid tumors. In this study, we demonstrate that genetic deletion and pharmacologic inhibition of FAP inhibited tumor growth in both an endogenous mouse model of lung cancer driven by the K-rasG12D mutant and a mouse model of colon cancer, in which CT26 mouse colon cancer cells were transplanted into immune competent syngeneic mice. Interestingly, growth of only the K-rasG12D-driven lung tumors was also attenuated by inhibition of the closely related protease dipeptidyl peptidase IV (DPPIV). Our results indicate that FAP depletion inhibits tumor cell proliferation indirectly, increases accumulation of collagen, decreases myofibroblast content, and decreases blood vessel density in tumors. These data provide proof of principle that targeting stromal cell-mediated modifications of the tumor microenvironment may be an effective approach to treating epithelial-derived solid tumors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Down-regulation of BRCA2 Expression by Collagen Type I Promotes Prostate Cancer Cell Proliferation
Moro, L., Arbini, A., Marra, E., & Greco, M. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m414091200 · Cited by 31
RetractedKalluri, R., & Zeisberg, M. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1877 · Cited by 4,538
Orimo, A., Gupta, P. B., Sgroi, D. C., Arenzana-Seisdedos, F., Delaunay, T., Naeem, R., Carey, V. J., Richardson, A. L., & Weinberg, R. A. (2005) · Cell · doi:10.1016/j.cell.2005.02.034 · Cited by 3,759
Somatic mutations affect key pathways in lung adenocarcinoma
Ding, L., Getz, G., Wheeler, D. A., Mardis, E. R., McLellan, M. D., Cibulskis, K., Sougnez, C., Greulich, H., Muzny, D. M., Morgan, M. B., et al. (2008) · Nature · doi:10.1038/nature07423 · Cited by 2,681
Stromal fibroblasts in cancer initiation and progression
Bhowmick, N. A., Neilson, E. G., & Moses, H. L. (2004) · Nature · doi:10.1038/nature03096 · Cited by 2,302
Willett, C. G., Boucher, Y., di Tomaso, E., Duda, D. G., Munn, L. L., Tong, R. T., Chung, D. C., Sahani, D. V., Kalva, S. P., Kozin, S. V., et al. (2004) · Nature Medicine · doi:10.1038/nm988 · Cited by 1,966
Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras
Jackson, E. L., Willis, N., Mercer, K., Bronson, R. T., Crowley, D., Montoya, R., Jacks, T., & Tuveson, D. A. (2001) · Genes & Development · doi:10.1101/gad.943001 · Cited by 1,898
Collagen reorganization at the tumor-stromal interface facilitates local invasion
Provenzano, P. P., Eliceiri, K. W., Campbell, J. M., Inman, D. R., White, J. G., & Keely, P. J. (2006) · BMC Medicine · doi:10.1186/1741-7015-4-38 · Cited by 1,804
Somatic activation of the K-ras oncogene causes early onset lung cancer in mice
Johnson, L., Mercer, K., Greenbaum, D., Bronson, R. T., Crowley, D., Tuveson, D. A., & Jacks, T. (2001) · Nature · doi:10.1038/35074129 · Cited by 1,179
Endothelial-pericyte interactions in angiogenesis
Gerhardt, H., & Betsholtz, C. (2003) · Cell and Tissue Research · doi:10.1007/s00441-003-0745-x · Cited by 1,057
Cited by
Turning foes to friends: targeting cancer-associated fibroblasts
Chen, X., & Song, E. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-018-0004-1 · Cited by 1,879
Hallmarks of cancer: Interactions with the tumor stroma
Pietras, K., & Östman, A. (2010) · Experimental Cell Research · doi:10.1016/j.yexcr.2010.02.045 · Cited by 1,141
Suppression of Antitumor Immunity by Stromal Cells Expressing Fibroblast Activation Protein–α
Kraman, M., Bambrough, P. J., Arnold, J. N., Roberts, E. W., Magiera, L., Jones, J. O., Gopinathan, A., Tuveson, D. A., & Fearon, D. T. (2010) · Science · doi:10.1126/science.1195300 · Cited by 1,134
Fibroblast heterogeneity in the cancer wound
Öhlund, D., Elyada, E., & Tuveson, D. (2014) · Journal of Experimental Medicine · doi:10.1084/jem.20140692 · Cited by 926
Dominguez, C. X., Müller, S., Keerthivasan, S., Koeppen, H., Hung, J., Gierke, S., Breart, B., Foreman, O., Bainbridge, T. W., Castiglioni, A., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-0644 · Cited by 857
Signaling pathways in cancer-associated fibroblasts and targeted therapy for cancer
Wu, F., Yang, J., Liu, J., Wang, Y., Mu, J., Zeng, Q., Deng, S., & Zhou, H. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00641-0 · Cited by 773
Yang, X., Lin, Y., Shi, Y., Li, B., Liu, W., Yin, W., Dang, Y., Chu, Y., Fan, J., & He, R. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-2973 · Cited by 748
Carcinoma-associated fibroblasts: orchestrating the composition of malignancy
Gascard, P., & Tlsty, T. D. (2016) · Genes & Development · doi:10.1101/gad.279737.116 · Cited by 732
Bremnes, R. M., Dønnem, T., Al-Saad, S., Al-Shibli, K., Andersen, S., Sirera, R., Camps, C., Marinez, I., & Busund, L.-T. (2011) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3181f8a1bd · Cited by 691
Monteran, L., & Erez, N. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01835 · Cited by 675
Wang, L.-C. S., Lo, A., Scholler, J., Sun, J., Majumdar, R. S., Kapoor, V., Antzis, M., Cotner, C. E., Johnson, L. A., Durham, A. C., et al. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-13-0027 · Cited by 653
Self-citationCancer-associated fibroblasts in gastrointestinal cancer
Kobayashi, H., Enomoto, A., Woods, S. L., Burt, A. D., Takahashi, M., & Worthley, D. L. (2019) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-019-0115-0 · Cited by 589
The role of fibroblast activation protein in health and malignancy
Fitzgerald, A. A., & Weiner, L. M. (2020) · Cancer and Metastasis Reviews · doi:10.1007/s10555-020-09909-3 · Cited by 589
Progression and metastasis of lung cancer
Popper, H. H. (2016) · Cancer and Metastasis Reviews · doi:10.1007/s10555-016-9618-0 · Cited by 545
Activation of fibroblasts in cancer stroma
Räsänen, K., & Vaheri, A. (2010) · Experimental Cell Research · doi:10.1016/j.yexcr.2010.04.032 · Cited by 499
“[66] demonstrated that enzymatic activity of FAP promotes tumor growth and genetic depletion of its expression, or even partial inhibition of its enzymatic activity by pharmacological inhibitor (PT630) indirectly reduced tumor cell proliferation, myofibroblast content and angiogenesis.”
BackgroundTumor-Promoting Desmoplasia Is Disrupted by Depleting FAP-Expressing Stromal Cells
Lo, A., Wang, L.-C. S., Scholler, J., Monslow, J., Avery, D., Newick, K., O'Brien, S., Evans, R. A., Bajor, D. J., Clendenin, C., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-3041 · Cited by 498
Self-citationHamson, E. J., Keane, F. M., Tholen, S., Schilling, O., & Gorrell, M. D. (2014) · PROTEOMICS – Clinical Applications · doi:10.1002/prca.201300095 · Cited by 496
Fibroblasts in cancer: Unity in heterogeneity
Chhabra, Y., & Weeraratna, A. T. (2023) · Cell · doi:10.1016/j.cell.2023.03.016 · Cited by 474
Tran, E., Chinnasamy, D., Yu, Z., Morgan, R. A., Lee, C.-C. R., Restifo, N. P., & Rosenberg, S. A. (2013) · Journal of Experimental Medicine · doi:10.1084/jem.20130110 · Cited by 463
Tumour-associated mesenchymal stem/stromal cells: emerging therapeutic targets
Shi, Y., Du, L., Lin, L., & Wang, Y. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.193 · Cited by 460
Roberts, E. W., Deonarine, A., Jones, J. O., Denton, A. E., Feig, C., Lyons, S. K., Espeli, M., Kraman, M., McKenna, B., Wells, R. J. B., et al. (2013) · Journal of Experimental Medicine · doi:10.1084/jem.20122344 · Cited by 414
Mesenchymal Cells of the Intestinal Lamina Propria
Powell, D. W., Pinchuk, I. V., Saada, J. I., Chen, X., & Mifflin, R. C. (2011) · Annual Review of Physiology · doi:10.1146/annurev.physiol.70.113006.100646 · Cited by 394
Pro-tumorigenic roles of fibroblast activation protein in cancer: back to the basics
Puré, E., & Blomberg, R. (2018) · Oncogene · doi:10.1038/s41388-018-0275-3 · Cited by 391
Self-citationMikhaylov, G., Mikac, U., Magaeva, A. A., Itin, V. I., Naiden, E. P., Psakhye, I., Babes, L., Reinheckel, T., Peters, C., Zeiser, R., et al. (2011) · Nature Nanotechnology · doi:10.1038/nnano.2011.112 · Cited by 383
Cancer associated fibroblasts: An essential role in the tumor microenvironment
Tao, L., Huang, G., Song, H., Chen, Y., & Chen, L. (2017) · Oncology Letters · doi:10.3892/ol.2017.6497 · Cited by 351
“FAP has been shown to support tumor growth and proliferation, making it a potential target for novel anticancer therapies (94).”
InfluentialAntitumor Effects of Chimeric Receptor Engineered Human T Cells Directed to Tumor Stroma
Kakarla, S., Chow, K. K., Mata, M., Shaffer, D. R., Song, X.-T., Wu, M.-F., Liu, H., Wang, L. L., Rowley, D. R., Pfizenmaier, K., et al. (2013) · Molecular Therapy · doi:10.1038/mt.2013.110 · Cited by 346
Barreira da Silva, R., Laird, M. E., Yatim, N., Fiette, L., Ingersoll, M. A., & Albert, M. L. (2015) · Nature Immunology · doi:10.1038/ni.3201 · Cited by 337
Cancer-associated fibroblasts in tumor microenvironment–Accomplices in tumor malignancy
Liao, Z., Tan, Z. W., Zhu, P., & Tan, N. S. (2019) · Cellular Immunology · doi:10.1016/j.cellimm.2017.12.003 · Cited by 335
Microenvironmental Determinants of Pancreatic Cancer
Hessmann, E., Buchholz, S. M., Demir, I. E., Singh, S. K., Gress, T. M., Ellenrieder, V., & Neesse, A. (2020) · Physiological Reviews · doi:10.1152/physrev.00042.2019 · Cited by 331
Valencia, T., Kim, J. Y., Abu-Baker, S., Moscat-Pardos, J., Ahn, C. S., Reina-Campos, M., Duran, A., Castilla, E. A., Metallo, C. M., Diaz-Meco, M. T., et al. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.05.004 · Cited by 304
CAF Subpopulations: A New Reservoir of Stromal Targets in Pancreatic Cancer
Pereira, B. A., Vennin, C., Papanicolaou, M., Chambers, C. R., Herrmann, D., Morton, J. P., Cox, T. R., & Timpson, P. (2019) · Trends in Cancer · doi:10.1016/j.trecan.2019.09.010 · Cited by 314
(2022) · doi:10.1158/2159-8290.cd-20-1484 · Cited by 311
Lee, H.-O., Mullins, S. R., Franco-Barraza, J., Valianou, M., Cukierman, E., & Cheng, J. D. (2011) · BMC Cancer · doi:10.1186/1471-2407-11-245 · Cited by 304
Biomarkers for cancer-associated fibroblasts
Han, C., Liu, T., & Yin, R. (2020) · Biomarker Research · doi:10.1186/s40364-020-00245-w · Cited by 299
Fearon, D. T. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0002 · Cited by 288
Brennen, W. N., Isaacs, J. T., & Denmeade, S. R. (2012) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0340 · Cited by 289
Jansen, K., Heirbaut, L., Verkerk, R., Cheng, J. D., Joossens, J., Cos, P., Maes, L., Lambeir, A.-M., De Meester, I., Augustyns, K., et al. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm500031w · Cited by 287
Cancer‐associated fibroblasts in breast cancer: Challenges and opportunities
Hu, D., Li, Z., Zheng, B., Lin, X., Pan, Y., Gong, P., Zhuo, W., Hu, Y., Chen, C., Chen, L., et al. (2022) · Cancer Communications · doi:10.1002/cac2.12291 · Cited by 286
Caveolin-1 and Cancer Metabolism in the Tumor Microenvironment: Markers, Models, and Mechanisms
Sotgia, F., Martinez-Outschoorn, U. E., Howell, A., Pestell, R. G., Pavlides, S., & Lisanti, M. P. (2012) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-011811-120856 · Cited by 281
Jansen, K., Heirbaut, L., Cheng, J. D., Joossens, J., Ryabtsova, O., Cos, P., Maes, L., Lambeir, A.-M., De Meester, I., Augustyns, K., et al. (2013) · ACS Medicinal Chemistry Letters · doi:10.1021/ml300410d · Cited by 260
Fibroblast heterogeneity in tumor micro-environment: Role in immunosuppression and new therapies
Mhaidly, R., & Mechta-Grigoriou, F. (2020) · Seminars in Immunology · doi:10.1016/j.smim.2020.101417 · Cited by 259
Molecular imaging of the tumor microenvironment
Zhou, Z., & Lu, Z.-R. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2016.07.012 · Cited by 253
The double edge sword of fibrosis in cancer
Chandler, C., Liu, T., Buckanovich, R., & Coffman, L. G. (2019) · Translational Research · doi:10.1016/j.trsl.2019.02.006 · Cited by 242
“Additionally, depletion of FAP via genetic KO or pharmacologic inhibition decreases lung and colon cancer growth.(149) Selective depletion of FAP+ CAFs via expression of the human diphtheria toxin receptor in FAP+ cells followed by diphtheria toxin administration enhances antitumor immunity and induces synergistic eff…”
BackgroundTissue Force Programs Cell Fate and Tumor Aggression
Northey, J. J., Przybyla, L., & Weaver, V. M. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-0733 · Cited by 237
“Thus, ablation of the fibroblast activation protein–positive stromal fibroblasts repressed pancreatic tumor progression (94, 95).”
BackgroundCancer associated fibroblasts in cancer development and therapy
Jia, H., Chen, X., Zhang, L., & Chen, M. (2025) · Journal of Hematology & Oncology · doi:10.1186/s13045-025-01688-0 · Cited by 224
“While the current evidence largely supports the notion that ECM stiffness exerts a tumor-promoting effect, a few studies have conversely found that a reduction in ECM components could facilitate tumor progression [77–79].”
Tumor microenvironment in ovarian cancer: function and therapeutic strategy
Yang, Y., Yang, Y., Yang, J., Zhao, X., & Wei, X. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.00758 · Cited by 218
“Studies have shown that inhibition of FAP can reduce the infiltration of CAF (Santos et al., 2009).”
BackgroundExtracellular matrix directs phenotypic heterogeneity of activated fibroblasts
Avery, D., Govindaraju, P., Jacob, M., Todd, L., Monslow, J., & Puré, E. (2018) · Matrix Biology · doi:10.1016/j.matbio.2017.12.003 · Cited by 206
Self-citationXin, L., Gao, J., Zheng, Z., Chen, Y., Lv, S., Zhao, Z., Yu, C., Yang, X., & Zhang, R. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.648187 · Cited by 203
Looi, C.-K., Chung, F. F.-L., Leong, C.-O., Wong, S.-F., Rosli, R., & Mai, C.-W. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1153-8 · Cited by 202
Shi, M. (2012) · World Journal of Gastroenterology · doi:10.3748/wjg.v18.i8.840 · Cited by 199
Drug targeting to myofibroblasts: Implications for fibrosis and cancer
Yazdani, S., Bansal, R., & Prakash, J. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2017.07.010 · Cited by 189
Brennen, W. N., Rosen, D. M., Wang, H., Isaacs, J. T., & Denmeade, S. R. (2012) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djs336 · Cited by 188
Govindaraju, P., Todd, L., Shetye, S., Monslow, J., & Puré, E. (2019) · Matrix Biology · doi:10.1016/j.matbio.2018.06.004 · Cited by 170
“Hydroxyproline assay was conducted as previously described [85].”
MethodSelf-citationCancer Stem Cells and Their Microenvironment: Biology and Therapeutic Implications
Lau, E. Y.-T., Ho, N. P.-Y., & Lee, T. K.-W. (2017) · Stem Cells International · doi:10.1155/2017/3714190 · Cited by 167
“PT630 (FAP inhibitor) FAP-α Preclinical [5]”
Fibroblast Activation Protein Cleaves and Inactivates Fibroblast Growth Factor 21
Dunshee, D. R., Bainbridge, T. W., Kljavin, N. M., Zavala-Solorio, J., Schroeder, A. C., Chan, R., Corpuz, R., Wong, M., Zhou, W., Deshmukh, G., et al. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.710582 · Cited by 158
“Fap-deficient mice do not show an overt phenotype (43), and they exhibit less severe cartilage degradation in a chronic inflammatory arthritis model (48) and are protected from tumorigenesis (49).”
BackgroundCirculating FGF21 proteolytic processing mediated by fibroblast activation protein
Zhen, E. Y., Jin, Z., Ackermann, B. L., Thomas, M. K., & Gutierrez, J. A. (2016) · Biochemical Journal · doi:10.1042/bj20151085 · Cited by 123
Scharl, M., Huber, N., Lang, S., Fürst, A., Jehle, E., & Rogler, G. (2015) · Clinical and Translational Medicine · doi:10.1186/s40169-015-0046-5 · Cited by 118
“A recent study even suggested that FAP inhibition might be beneficial for treating epithelial-derived tumours, since pharmacologic targeting of FAP inhibited tumour stromagenesis by affecting integrin-mediated signalling and led to a decreased recruitment and overall number of myofibroblasts [27].”
BackgroundWang, F., Sun, W., Zhang, J., & Fan, Y. (2019) · Oncology Letters · doi:10.3892/ol.2019.9973 · Cited by 115
Slama, Y., Ah-Pine, F., Khettab, M., Arcambal, A., Begue, M., Dutheil, F., & Gasque, P. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241713511 · Cited by 57
Hsu, T.-H., Kao, Y.-L., Lin, W.-L., Xiao, J.-L., Kuo, P.-L., Wu, C.-W., Liao, W.-Y., & Lee, C.-H. (2012) · Integr. Biol. · doi:10.1039/c2ib00112h · Cited by 47
Repurposing drugs targeting metabolic diseases for cancer therapeutics
Pillai U, J., Ray, A., Maan, M., & Dutta, M. (2023) · Drug Discovery Today · doi:10.1016/j.drudis.2023.103684 · Cited by 31
Metadata
- Authors
- Santos, A. M., Jung, J., Aziz, N., Kissil, J. L., & Puré, E.
- Venue
- Journal of Clinical Investigation
- Published
- 2009-12-01
- Volume
- 119
- Issue
- 12
- Pages
- 3613-3625
- ISSN
- 0021-9738 (ISSN-L)
- OpenAlex
- W2039675196
- Cited by
- 428
- References
- 58
- FWCI
- 8.80
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.